Clinical Trial Update: Ibrutinib With or Without Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia [Phase 2]

View source ↗

Summary

A Phase 2 trial is evaluating ibrutinib with or without rituximab in patients with relapsed chronic lymphocytic leukemia and related lymphoproliferative disease…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Prolymphocytic Leukemia
• Small Lymphocytic Lymphoma

Drugs mentioned

• IMBRUVICA (IBRUTINIB)
• Rituxan (rituximab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Prolymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia | Phase 2 | Status: ACTIVE_NOT_RECRUITING